Medical/Pharmaceuticals

No Picture
News

Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine

December 23, 2020 PR Newswire Releases Comments Off on Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine

PUNE, India and EMERYVILLE, Calif., Dec. 23, 2020 /PRNewswire/ — Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world’s largest vaccine manufacturer by volume, has partnered with Dynavax Technologies Corpora… […]

No Picture
News

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

December 23, 2020 PR Newswire Releases Comments Off on Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expr… […]

No Picture
News

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

December 23, 2020 PR Newswire Releases Comments Off on Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expr… […]

No Picture
News

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis

December 22, 2020 PR Newswire Releases Comments Off on Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis

SAN FRANCISCO, Dec. 22, 2020 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KI… […]

No Picture
News

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFa Antibody for Canine Inflammatory Bowel Disease

December 21, 2020 PR Newswire Releases Comments Off on Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFa Antibody for Canine Inflammatory Bowel Disease

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its mon… […]

No Picture
News

Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

December 21, 2020 PR Newswire Releases Comments Off on Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

Novel technology developed by Cleveland Clinic researchers

SAN JOSE, Calif., Dec. 21, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, anno… […]

No Picture
News

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

December 21, 2020 PR Newswire Releases Comments Off on BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated ChildrenNo New Safety Signals ObservedCurrent Regulatory Review Timelines on Track

SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ — BioMar… […]

No Picture
News

U.S. Patent Office Upholds Validity of Natera’s Early Priority Date ‘592 cfDNA Patent

December 18, 2020 PR Newswire Releases Comments Off on U.S. Patent Office Upholds Validity of Natera’s Early Priority Date ‘592 cfDNA Patent

SAN CARLOS, Calif., Dec. 18, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a patentabil… […]